文献速递前列腺癌

持续雄激素剥夺治疗联合或不联合转移灶导向治疗用于寡转移性前列腺癌:多中心2期随机EXTEND试验

Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial.
PubMed 文献 · Eur Urol · 2025-07-31

EXTEND试验纳入174例寡转移性前列腺癌患者,随机接受持续ADT或MDT+ADT。持续ADT组中,MDT+ADT组中位PFS为47个月,ADT组为22个月(HR 0.50,单侧p=0.036)。合并分析中,MDT+ADT组中位PFS为36个月,ADT组为17个月(HR 0.45,p<0.001),且影像学PFS和去势抵抗无生存期均更优。

要点

  • MDT+ADT较单用ADT显著延长寡转移性前列腺癌患者的PFS。
  • 持续ADT亚组中,MDT+ADT组中位PFS为47个月,ADT组为22个月。
  • MDT+ADT诱导更强的全身免疫激活,与持久临床缓解相关。

核心结论

  • 在寡转移性前列腺癌患者中,MDT+ADT较单用ADT改善PFS,需3期试验确认。
  • MDT+ADT诱导的免疫反应值得机制验证及未来T细胞靶向免疫治疗试验。

研究设计与样本

  • 多中心2期EXTEND试验,将寡转移性前列腺癌患者1:1随机分配至ADT或MDT+ADT。
  • 试验分为两个独立随机篮子:间歇ADT篮子和持续ADT篮子,主要终点为PFS。
  • 2018年9月至2022年8月,共174例患者随机入组并纳入主要分析。
  • 本文报告持续ADT篮子的主要结果、两个篮子的合并分析及转化免疫相关性。

主要发现

  • 持续ADT篮子(N=87)中,MDT+ADT组中位PFS为47个月,ADT组为22个月(HR 0.50,单侧p=0.036)。
  • 合并分析中,MDT+ADT组中位PFS为36个月,ADT组为17个月(HR 0.45,p<0.001)。
  • MDT+ADT组影像学PFS和去势抵抗无生存期均优于ADT组。
  • MDT+ADT后持久临床缓解与全身Th1极化细胞因子上调和CD8+ T细胞增殖相关。
  • MDT+ADT诱导更强的全身免疫激活,包括T细胞受体扩增/收缩,在独立ORIOLE试验中亦观察到。

临床怎么用

  • 对于寡转移性前列腺癌患者,可考虑在ADT基础上联合MDT以改善PFS。
  • MDT+ADT的免疫激活效应提示未来可探索T细胞靶向免疫治疗联合策略。

局限性

  • 为2期试验,结果需3期试验确认。
  • 免疫相关发现为假设生成性,需机制验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Oligometastatic prostate cancer (omPC) is characterized by limited metastases. We hypothesized that metastasis-directed therapy (MDT) to all sites of omPC combined with androgen deprivation therapy (ADT) would improve clinical outcomes. METHODS: In the multicenter phase 2 EXTEND trial, patients with omPC were randomized 1:1 to ADT versus MDT + ADT in two independently powered and randomized baskets, one using intermittent ADT and one using continuous ADT. The primary endpoint was progression-free survival (PFS). The secondary endpoints included radiologic PFS (rPFS) and castration resistance-free survival (CRFS). Here, the primary results of the continuous ADT basket, the combined analysis of both baskets, and translational immune correlatives are reported. KEY FINDINGS AND LIMITATIONS: From September 2018 through August 2022, 174 patients were randomized and were eligible for the primary analysis. In the continuous ADT basket (N = 87), the median PFS was 47 mo with MDT + ADT versus 22 mo with ADT (hazard ratio [HR], 0.50; one-sided p = 0.036). In the combined analysis, the median PFS was 36 mo with MDT + ADT versus 17 mo with ADT (HR, 0.45; p < 0.001). Radiologic PFS and CRFS were also superior with MDT + ADT. Durable clinical responses after MDT + ADT were associated with systemic Th1-polarizing cytokine upregulation and CD8+ T-cell proliferation. Compared with ADT, MDT + ADT induced greater systemic immune activation, including T-cell receptor expansion/contraction, which we also observed in the independent ORIOLE trial of MDT. The greatest PFS benefit after MDT + ADT was observed in patients with systemic T-cell receptor expansion/contraction. CONCLUSIONS AND CLINICAL IMPLICATIONS: MDT + ADT improves PFS compared with ADT in omPC patients, meriting phase 3 confirmation. Hypothesis-generating immune responses warrant mechanistic validation and future trials with T-cell-targeted immunotherapies.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Sherry AD, Siddiqui BA, Haymaker C, et al. Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial. Eur Urol. 2025. PMID: 40750497. doi:10.1016/j.eururo.2025.07.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。